APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid Induced Constipation Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Opioid Induced Constipation Drugs Industry Research Report 2026

20 December 2025137 pages

Choose your research edition.

Industry ResearchOpioid Induced Constipation Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Induced Constipation Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Opioid Induced Constipation Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Induced Constipation Drugs Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Induced Constipation Drugs Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Opioid Induced Constipation Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Opioid Induced Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Opioid Induced Constipation Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Opioid Induced Constipation Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Opioid Induced Constipation Drugs include Allergan Plc, Bausch Health, C.B. Fleet Company, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Mundipharma International Limited and Nektar Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Opioid Induced Constipation Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Opioid Induced Constipation Drugs Market by Company

Allergan Plc

Bausch Health

C.B. Fleet Company

Cosmo Pharmaceuticals SA

Daewoong Pharmaceutical

Daiichi Sankyo Co Ltd

Ironwood Pharmaceuticals Inc

Mundipharma International Limited

Nektar Therapeutics

Ono Pharmaceutical Co., Ltd

Progenics Pharmaceuticals Inc

Purdue Pharma

S.L.A. Pharma AG

Shionogi & Co., Ltd

Sucampo Pharmaceuticals

Theravance Biopharma Inc

Pfizer

Takeda Pharmaceutical Company Limited

Opioid Induced Constipation Drugs Segment by Type

Lubiprostone

Methyl Naltrexone Bromide

Naldemedine

Alvimopan

Others

Opioid Induced Constipation Drugs Segment by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Opioid Induced Constipation Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Induced Constipation Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Induced Constipation Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Induced Constipation Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Opioid Induced Constipation Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Opioid Induced Constipation Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Opioid Induced Constipation Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Opioid Induced Constipation Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Opioid Induced Constipation Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Opioid Induced Constipation Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Opioid Induced Constipation Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Opioid Induced Constipation Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Opioid Induced Constipation Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Opioid Induced Constipation Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Opioid Induced Constipation Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Opioid Induced Constipation Drugs, Product Type & Application Table 14. Global Opioid Induced Constipation Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Opioid Induced Constipation Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Allergan Plc Company Information Table 19. Allergan Plc Business Overview Table 20. Allergan Plc Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Allergan Plc Opioid Induced Constipation Drugs Product Portfolio Table 22. Allergan Plc Recent Developments Table 23. Bausch Health Company Information Table 24. Bausch Health Business Overview Table 25. Bausch Health Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Bausch Health Opioid Induced Constipation Drugs Product Portfolio Table 27. Bausch Health Recent Developments Table 28. C.B. Fleet Company Company Information Table 29. C.B. Fleet Company Business Overview Table 30. C.B. Fleet Company Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. C.B. Fleet Company Opioid Induced Constipation Drugs Product Portfolio Table 32. C.B. Fleet Company Recent Developments Table 33. Cosmo Pharmaceuticals SA Company Information Table 34. Cosmo Pharmaceuticals SA Business Overview Table 35. Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Product Portfolio Table 37. Cosmo Pharmaceuticals SA Recent Developments Table 38. Daewoong Pharmaceutical Company Information Table 39. Daewoong Pharmaceutical Business Overview Table 40. Daewoong Pharmaceutical Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Daewoong Pharmaceutical Opioid Induced Constipation Drugs Product Portfolio Table 42. Daewoong Pharmaceutical Recent Developments Table 43. Daiichi Sankyo Co Ltd Company Information Table 44. Daiichi Sankyo Co Ltd Business Overview Table 45. Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Product Portfolio Table 47. Daiichi Sankyo Co Ltd Recent Developments Table 48. Ironwood Pharmaceuticals Inc Company Information Table 49. Ironwood Pharmaceuticals Inc Business Overview Table 50. Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Product Portfolio Table 52. Ironwood Pharmaceuticals Inc Recent Developments Table 53. Mundipharma International Limited Company Information Table 54. Mundipharma International Limited Business Overview Table 55. Mundipharma International Limited Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Mundipharma International Limited Opioid Induced Constipation Drugs Product Portfolio Table 57. Mundipharma International Limited Recent Developments Table 58. Nektar Therapeutics Company Information Table 59. Nektar Therapeutics Business Overview Table 60. Nektar Therapeutics Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Nektar Therapeutics Opioid Induced Constipation Drugs Product Portfolio Table 62. Nektar Therapeutics Recent Developments Table 63. Ono Pharmaceutical Co., Ltd Company Information Table 64. Ono Pharmaceutical Co., Ltd Business Overview Table 65. Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Product Portfolio Table 67. Ono Pharmaceutical Co., Ltd Recent Developments Table 68. Progenics Pharmaceuticals Inc Company Information Table 69. Progenics Pharmaceuticals Inc Business Overview Table 70. Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Product Portfolio Table 72. Progenics Pharmaceuticals Inc Recent Developments Table 73. Purdue Pharma Company Information Table 74. Purdue Pharma Business Overview Table 75. Purdue Pharma Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Purdue Pharma Opioid Induced Constipation Drugs Product Portfolio Table 77. Purdue Pharma Recent Developments Table 78. S.L.A. Pharma AG Company Information Table 79. S.L.A. Pharma AG Business Overview Table 80. S.L.A. Pharma AG Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. S.L.A. Pharma AG Opioid Induced Constipation Drugs Product Portfolio Table 82. S.L.A. Pharma AG Recent Developments Table 83. Shionogi & Co., Ltd Company Information Table 84. Shionogi & Co., Ltd Business Overview Table 85. Shionogi & Co., Ltd Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Shionogi & Co., Ltd Opioid Induced Constipation Drugs Product Portfolio Table 87. Shionogi & Co., Ltd Recent Developments Table 88. Sucampo Pharmaceuticals Company Information Table 89. Sucampo Pharmaceuticals Business Overview Table 90. Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Product Portfolio Table 92. Sucampo Pharmaceuticals Recent Developments Table 93. Theravance Biopharma Inc Company Information Table 94. Theravance Biopharma Inc Business Overview Table 95. Theravance Biopharma Inc Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Theravance Biopharma Inc Opioid Induced Constipation Drugs Product Portfolio Table 97. Theravance Biopharma Inc Recent Developments Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Pfizer Opioid Induced Constipation Drugs Product Portfolio Table 102. Pfizer Recent Developments Table 103. Takeda Pharmaceutical Company Limited Company Information Table 104. Takeda Pharmaceutical Company Limited Business Overview Table 105. Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Product Portfolio Table 107. Takeda Pharmaceutical Company Limited Recent Developments Table 108. Global Opioid Induced Constipation Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Opioid Induced Constipation Drugs Sales by Region (2021-2026) & (K Units) Table 110. Global Opioid Induced Constipation Drugs Sales Market Share by Region (2021-2026) Table 111. Global Opioid Induced Constipation Drugs Sales by Region (2027-2032) & (K Units) Table 112. Global Opioid Induced Constipation Drugs Sales Market Share by Region (2027-2032) Table 113. Global Opioid Induced Constipation Drugs Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Opioid Induced Constipation Drugs Revenue Market Share by Region (2021-2026) Table 115. Global Opioid Induced Constipation Drugs Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Opioid Induced Constipation Drugs Revenue Market Share by Region (2027-2032) Table 117. North America Opioid Induced Constipation Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Opioid Induced Constipation Drugs Sales by Country (2021-2026) & (K Units) Table 119. North America Opioid Induced Constipation Drugs Sales by Country (2027-2032) & (K Units) Table 120. North America Opioid Induced Constipation Drugs Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Opioid Induced Constipation Drugs Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Opioid Induced Constipation Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Opioid Induced Constipation Drugs Sales by Country (2021-2026) & (K Units) Table 124. Europe Opioid Induced Constipation Drugs Sales by Country (2027-2032) & (K Units) Table 125. Europe Opioid Induced Constipation Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Opioid Induced Constipation Drugs Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Opioid Induced Constipation Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Opioid Induced Constipation Drugs Sales by Country (2021-2026) & (K Units) Table 129. Asia Pacific Opioid Induced Constipation Drugs Sales by Country (2027-2032) & (K Units) Table 130. Asia Pacific Opioid Induced Constipation Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Opioid Induced Constipation Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Opioid Induced Constipation Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Opioid Induced Constipation Drugs Sales by Country (2021-2026) & (K Units) Table 134. South America Opioid Induced Constipation Drugs Sales by Country (2027-2032) & (K Units) Table 135. South America Opioid Induced Constipation Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Opioid Induced Constipation Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Opioid Induced Constipation Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Opioid Induced Constipation Drugs Sales by Country (2021-2026) & (K Units) Table 139. Middle East and Africa Opioid Induced Constipation Drugs Sales by Country (2027-2032) & (K Units) Table 140. Middle East and Africa Opioid Induced Constipation Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Opioid Induced Constipation Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Opioid Induced Constipation Drugs Sales by Type (2021-2026) & (K Units) Table 143. Global Opioid Induced Constipation Drugs Sales by Type (2027-2032) & (K Units) Table 144. Global Opioid Induced Constipation Drugs Sales Market Share by Type (2021-2026) Table 145. Global Opioid Induced Constipation Drugs Sales Market Share by Type (2027-2032) Table 146. Global Opioid Induced Constipation Drugs Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Opioid Induced Constipation Drugs Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Opioid Induced Constipation Drugs Revenue Market Share by Type (2021-2026) Table 149. Global Opioid Induced Constipation Drugs Revenue Market Share by Type (2027-2032) Table 150. Global Opioid Induced Constipation Drugs Price by Type (2021-2026) & (US$/Unit) Table 151. Global Opioid Induced Constipation Drugs Price by Type (2027-2032) & (US$/Unit) Table 152. Global Opioid Induced Constipation Drugs Sales by Application (2021-2026) & (K Units) Table 153. Global Opioid Induced Constipation Drugs Sales by Application (2027-2032) & (K Units) Table 154. Global Opioid Induced Constipation Drugs Sales Market Share by Application (2021-2026) Table 155. Global Opioid Induced Constipation Drugs Sales Market Share by Application (2027-2032) Table 156. Global Opioid Induced Constipation Drugs Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Opioid Induced Constipation Drugs Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Opioid Induced Constipation Drugs Revenue Market Share by Application (2021-2026) Table 159. Global Opioid Induced Constipation Drugs Revenue Market Share by Application (2027-2032) Table 160. Global Opioid Induced Constipation Drugs Price by Application (2021-2026) & (US$/Unit) Table 161. Global Opioid Induced Constipation Drugs Price by Application (2027-2032) & (US$/Unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Opioid Induced Constipation Drugs Distributors List Table 165. Opioid Induced Constipation Drugs Customers List Table 166. Opioid Induced Constipation Drugs Industry Trends Table 167. Opioid Induced Constipation Drugs Industry Drivers Table 168. Opioid Induced Constipation Drugs Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Opioid Induced Constipation Drugs Product Image Figure 5. Global Opioid Induced Constipation Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Opioid Induced Constipation Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Opioid Induced Constipation Drugs Sales (2021-2032) & (K Units) Figure 8. Global Opioid Induced Constipation Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Lubiprostone Product Image Figure 10. Methyl Naltrexone Bromide Product Image Figure 11. Naldemedine Product Image Figure 12. Alvimopan Product Image Figure 13. Others Product Image Figure 14. Hospital Pharmacies Product Image Figure 15. Retail Pharmacies Product Image Figure 16. Online Pharmacies Product Image Figure 17. Global Opioid Induced Constipation Drugs Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Opioid Induced Constipation Drugs, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Opioid Induced Constipation Drugs Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Opioid Induced Constipation Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Opioid Induced Constipation Drugs Sales by Region in 2025 Figure 23. Global Opioid Induced Constipation Drugs Revenue by Region in 2025 Figure 24. North America Opioid Induced Constipation Drugs Market Size by Country in 2025 Figure 25. North America Opioid Induced Constipation Drugs Sales Market Share by Country (2021-2032) Figure 26. North America Opioid Induced Constipation Drugs Revenue Market Share by Country (2021-2032) Figure 27. United States Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Opioid Induced Constipation Drugs Market Size by Country in 2025 Figure 30. Europe Opioid Induced Constipation Drugs Sales Market Share by Country (2021-2032) Figure 31. Europe Opioid Induced Constipation Drugs Revenue Market Share by Country (2021-2032) Figure 32. Germany Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Nordic Countries Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Asia Pacific Opioid Induced Constipation Drugs Market Size by Country in 2025 Figure 39. Asia Pacific Opioid Induced Constipation Drugs Sales Market Share by Country (2021-2032) Figure 40. Asia Pacific Opioid Induced Constipation Drugs Revenue Market Share by Country (2021-2032) Figure 41. China Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Japan Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. South Korea Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. India Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Australia Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. China Taiwan Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South America Opioid Induced Constipation Drugs Market Size by Country in 2025 Figure 50. South America Opioid Induced Constipation Drugs Sales Market Share by Country (2021-2032) Figure 51. South America Opioid Induced Constipation Drugs Revenue Market Share by Country (2021-2032) Figure 52. Mexico Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Brazil Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Colombia Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa Opioid Induced Constipation Drugs Market Size by Country in 2025 Figure 57. Middle East and Africa Opioid Induced Constipation Drugs Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa Opioid Induced Constipation Drugs Revenue Market Share by Country (2021-2032) Figure 59. Turkey Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. UAE Opioid Induced Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Global Opioid Induced Constipation Drugs Sales Market Share by Type (2021-2032) Figure 63. Global Opioid Induced Constipation Drugs Revenue Market Share by Type (2021-2032) Figure 64. Global Opioid Induced Constipation Drugs Price (US$/Unit) by Type (2021-2032) Figure 65. Global Opioid Induced Constipation Drugs Sales Market Share by Application (2021-2032) Figure 66. Global Opioid Induced Constipation Drugs Revenue Market Share by Application (2021-2032) Figure 67. Global Opioid Induced Constipation Drugs Price (US$/Unit) by Application (2021-2032) Figure 68. Opioid Induced Constipation Drugs Value Chain Figure 69. Opioid Induced Constipation Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Opioid Induced Constipation Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Lubiprostone
  • Methyl Naltrexone Bromide
  • Naldemedine
  • Alvimopan
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Companies covered
  • Allergan Plc
  • Bausch Health
  • C.B. Fleet Company
  • Cosmo Pharmaceuticals SA
  • Daewoong Pharmaceutical
  • Daiichi Sankyo Co Ltd
  • Ironwood Pharmaceuticals Inc
  • Mundipharma International Limited
  • Nektar Therapeutics
  • Ono Pharmaceutical Co., Ltd
  • Progenics Pharmaceuticals Inc
  • Purdue Pharma
  • S.L.A. Pharma AG
  • Shionogi & Co., Ltd
  • Sucampo Pharmaceuticals
  • Theravance Biopharma Inc
  • Pfizer
  • Takeda Pharmaceutical Company Limited

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Opioid Induced Constipation Drugs Market Size (2021-2032)
  4. 2.2.2 Global Opioid Induced Constipation Drugs Sales (2021-2032)
  5. 2.2.3 Global Opioid Induced Constipation Drugs Market Average Price (2021-2032)
  6. 2.3 Opioid Induced Constipation Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Lubiprostone
  9. 2.3.3 Methyl Naltrexone Bromide
  10. 2.3.4 Naldemedine
  11. 2.3.5 Alvimopan
  12. 2.3.6 Others
  13. 2.4 Opioid Induced Constipation Drugs by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital Pharmacies
  16. 2.4.3 Retail Pharmacies
  17. 2.4.4 Online Pharmacies
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Opioid Induced Constipation Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Opioid Induced Constipation Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Opioid Induced Constipation Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Opioid Induced Constipation Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Opioid Induced Constipation Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Opioid Induced Constipation Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Opioid Induced Constipation Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Opioid Induced Constipation Drugs, Established Date
  9. 3.9 Global Opioid Induced Constipation Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Allergan Plc
  2. 4.1.1 Allergan Plc Company Information
  3. 4.1.2 Allergan Plc Business Overview
  4. 4.1.3 Allergan Plc Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Allergan Plc Opioid Induced Constipation Drugs Product Portfolio
  6. 4.1.5 Allergan Plc Recent Developments
  7. 4.2 Bausch Health
  8. 4.2.1 Bausch Health Company Information
  9. 4.2.2 Bausch Health Business Overview
  10. 4.2.3 Bausch Health Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bausch Health Opioid Induced Constipation Drugs Product Portfolio
  12. 4.2.5 Bausch Health Recent Developments
  13. 4.3 C.B. Fleet Company
  14. 4.3.1 C.B. Fleet Company Company Information
  15. 4.3.2 C.B. Fleet Company Business Overview
  16. 4.3.3 C.B. Fleet Company Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 C.B. Fleet Company Opioid Induced Constipation Drugs Product Portfolio
  18. 4.3.5 C.B. Fleet Company Recent Developments
  19. 4.4 Cosmo Pharmaceuticals SA
  20. 4.4.1 Cosmo Pharmaceuticals SA Company Information
  21. 4.4.2 Cosmo Pharmaceuticals SA Business Overview
  22. 4.4.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Product Portfolio
  24. 4.4.5 Cosmo Pharmaceuticals SA Recent Developments
  25. 4.5 Daewoong Pharmaceutical
  26. 4.5.1 Daewoong Pharmaceutical Company Information
  27. 4.5.2 Daewoong Pharmaceutical Business Overview
  28. 4.5.3 Daewoong Pharmaceutical Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Daewoong Pharmaceutical Opioid Induced Constipation Drugs Product Portfolio
  30. 4.5.5 Daewoong Pharmaceutical Recent Developments
  31. 4.6 Daiichi Sankyo Co Ltd
  32. 4.6.1 Daiichi Sankyo Co Ltd Company Information
  33. 4.6.2 Daiichi Sankyo Co Ltd Business Overview
  34. 4.6.3 Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Product Portfolio
  36. 4.6.5 Daiichi Sankyo Co Ltd Recent Developments
  37. 4.7 Ironwood Pharmaceuticals Inc
  38. 4.7.1 Ironwood Pharmaceuticals Inc Company Information
  39. 4.7.2 Ironwood Pharmaceuticals Inc Business Overview
  40. 4.7.3 Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Product Portfolio
  42. 4.7.5 Ironwood Pharmaceuticals Inc Recent Developments
  43. 4.8 Mundipharma International Limited
  44. 4.8.1 Mundipharma International Limited Company Information
  45. 4.8.2 Mundipharma International Limited Business Overview
  46. 4.8.3 Mundipharma International Limited Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Mundipharma International Limited Opioid Induced Constipation Drugs Product Portfolio
  48. 4.8.5 Mundipharma International Limited Recent Developments
  49. 4.9 Nektar Therapeutics
  50. 4.9.1 Nektar Therapeutics Company Information
  51. 4.9.2 Nektar Therapeutics Business Overview
  52. 4.9.3 Nektar Therapeutics Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Nektar Therapeutics Opioid Induced Constipation Drugs Product Portfolio
  54. 4.9.5 Nektar Therapeutics Recent Developments
  55. 4.10 Ono Pharmaceutical Co., Ltd
  56. 4.10.1 Ono Pharmaceutical Co., Ltd Company Information
  57. 4.10.2 Ono Pharmaceutical Co., Ltd Business Overview
  58. 4.10.3 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Product Portfolio
  60. 4.10.5 Ono Pharmaceutical Co., Ltd Recent Developments
  61. 4.11 Progenics Pharmaceuticals Inc
  62. 4.11.1 Progenics Pharmaceuticals Inc Company Information
  63. 4.11.2 Progenics Pharmaceuticals Inc Business Overview
  64. 4.11.3 Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Product Portfolio
  66. 4.11.5 Progenics Pharmaceuticals Inc Recent Developments
  67. 4.12 Purdue Pharma
  68. 4.12.1 Purdue Pharma Company Information
  69. 4.12.2 Purdue Pharma Business Overview
  70. 4.12.3 Purdue Pharma Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Purdue Pharma Opioid Induced Constipation Drugs Product Portfolio
  72. 4.12.5 Purdue Pharma Recent Developments
  73. 4.13 S.L.A. Pharma AG
  74. 4.13.1 S.L.A. Pharma AG Company Information
  75. 4.13.2 S.L.A. Pharma AG Business Overview
  76. 4.13.3 S.L.A. Pharma AG Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 S.L.A. Pharma AG Opioid Induced Constipation Drugs Product Portfolio
  78. 4.13.5 S.L.A. Pharma AG Recent Developments
  79. 4.14 Shionogi & Co., Ltd
  80. 4.14.1 Shionogi & Co., Ltd Company Information
  81. 4.14.2 Shionogi & Co., Ltd Business Overview
  82. 4.14.3 Shionogi & Co., Ltd Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Shionogi & Co., Ltd Opioid Induced Constipation Drugs Product Portfolio
  84. 4.14.5 Shionogi & Co., Ltd Recent Developments
  85. 4.15 Sucampo Pharmaceuticals
  86. 4.15.1 Sucampo Pharmaceuticals Company Information
  87. 4.15.2 Sucampo Pharmaceuticals Business Overview
  88. 4.15.3 Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Product Portfolio
  90. 4.15.5 Sucampo Pharmaceuticals Recent Developments
  91. 4.16 Theravance Biopharma Inc
  92. 4.16.1 Theravance Biopharma Inc Company Information
  93. 4.16.2 Theravance Biopharma Inc Business Overview
  94. 4.16.3 Theravance Biopharma Inc Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Theravance Biopharma Inc Opioid Induced Constipation Drugs Product Portfolio
  96. 4.16.5 Theravance Biopharma Inc Recent Developments
  97. 4.17 Pfizer
  98. 4.17.1 Pfizer Company Information
  99. 4.17.2 Pfizer Business Overview
  100. 4.17.3 Pfizer Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Pfizer Opioid Induced Constipation Drugs Product Portfolio
  102. 4.17.5 Pfizer Recent Developments
  103. 4.18 Takeda Pharmaceutical Company Limited
  104. 4.18.1 Takeda Pharmaceutical Company Limited Company Information
  105. 4.18.2 Takeda Pharmaceutical Company Limited Business Overview
  106. 4.18.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Product Portfolio
  108. 4.18.5 Takeda Pharmaceutical Company Limited Recent Developments
5 Global Opioid Induced Constipation Drugs Market Scenario by Region
  1. 5.1 Global Opioid Induced Constipation Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Opioid Induced Constipation Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Opioid Induced Constipation Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Opioid Induced Constipation Drugs Sales by Region: 2027-2032
  5. 5.3 Global Opioid Induced Constipation Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Opioid Induced Constipation Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Opioid Induced Constipation Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Opioid Induced Constipation Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Opioid Induced Constipation Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Opioid Induced Constipation Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Opioid Induced Constipation Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Opioid Induced Constipation Drugs Market Facts & Figures by Country
  15. 5.5.1 Europe Opioid Induced Constipation Drugs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Opioid Induced Constipation Drugs Sales by Country (2021-2032)
  17. 5.5.3 Europe Opioid Induced Constipation Drugs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Opioid Induced Constipation Drugs Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Opioid Induced Constipation Drugs Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Opioid Induced Constipation Drugs Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Opioid Induced Constipation Drugs Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Opioid Induced Constipation Drugs Market Facts & Figures by Country
  36. 5.7.1 South America Opioid Induced Constipation Drugs Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Opioid Induced Constipation Drugs Sales by Country (2021-2032)
  38. 5.7.3 South America Opioid Induced Constipation Drugs Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.7.7 Colombia
  43. 5.8 Middle East and Africa Opioid Induced Constipation Drugs Market Facts & Figures by Country
  44. 5.8.1 Middle East and Africa Opioid Induced Constipation Drugs Market Size by Country: 2021 VS 2025 VS 2032
  45. 5.8.2 Middle East and Africa Opioid Induced Constipation Drugs Sales by Country (2021-2032)
  46. 5.8.3 Middle East and Africa Opioid Induced Constipation Drugs Revenue by Country (2021-2032)
  47. 5.8.4 Turkey
  48. 5.8.5 Saudi Arabia
  49. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Opioid Induced Constipation Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Opioid Induced Constipation Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Opioid Induced Constipation Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Opioid Induced Constipation Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Opioid Induced Constipation Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Opioid Induced Constipation Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Opioid Induced Constipation Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Opioid Induced Constipation Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Opioid Induced Constipation Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Opioid Induced Constipation Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Opioid Induced Constipation Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Opioid Induced Constipation Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Opioid Induced Constipation Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Opioid Induced Constipation Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Opioid Induced Constipation Drugs Value Chain Analysis
  2. 8.1.1 Opioid Induced Constipation Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Opioid Induced Constipation Drugs Production Mode & Process
  5. 8.2 Opioid Induced Constipation Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Opioid Induced Constipation Drugs Distributors
  8. 8.2.3 Opioid Induced Constipation Drugs Customers
9 Global Opioid Induced Constipation Drugs Analyzing Market Dynamics
  1. 9.1 Opioid Induced Constipation Drugs Industry Trends
  2. 9.2 Opioid Induced Constipation Drugs Industry Drivers
  3. 9.3 Opioid Induced Constipation Drugs Industry Opportunities and Challenges
  4. 9.4 Opioid Induced Constipation Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst